Kornimate/medical-research-clean huggingface dataset:
improved diagnosis of alzheimer's disease using the synchronous neural interaction™ test

Conditions: Alzheimer's Disease

Summary: this study is designed to test the hypothesis that the synchronous neural interaction™ test is useful for diagnosing probable alzheimer's disease according to standard criteria. subjects diagnosed with alzheimer's disease as well as age-matched normal control subjects will be evaluated for symptoms of alzheimer's disease and those meeting inclusion criteria will undergo a brief, non-invasive scan of brain function using a magnetoencephalography (meg). the scan itself lasts 1 minute while the subject is asked to stare at a dot projected in front of them on a video screen. orasi medical believes that patterns of brain activity measured at rest are indicative of alzheimer's disease pathology. the protocol is amended to add a follow-up assessment for previously enrolled and completed subjects who agree to participate in the follow-up assessment approximately 9 - 15 months after initial study enrollment. subjects who agree to participate in the follow-up assessment will undergo the same standardized tests and meg scan procedure as completed in the initial study.


Eligibility criteria:
inclusion criteria: 1. subject is between 18 and 90 years of age 2. i. provide written informed consent for study participation, or ii. provide written assent to study participant accompanied by the provision of written informed by the subject's legally authorized representative (lar); see section 8. informed consent for details of the procedures use to meet these study inclusion criteria 3. have one of the following clinical diagnoses or conditions: * probable ad according to the nincds-adrda criteria * possible ad according to the nincds-adrda criteria * prodromal ad according to criteria described by dubois \& albert (2004) * normal control subject exclusion criteria: 1. have a significant non-ad neurological condition including parkinson's disease, vascular dementia, lewy body dementia or frontal temporal dementia, human immunodeficiency virus, multiple sclerosis, epilepsy, or severe traumatic brain injury. 2. have dementia due to multiple etiologies (e.g. mixed dementia) 3. show the presence of prominent disturbances in gait thought to be associated with parkinsonism. 4. show prominent changes in personality or social conduct prior to the onset of prominent cognitive dysfunction 5. have a modified hachinski ischemia scale score of greater than 4 6. have a history of primary psychotic disorder (e.g schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder 7. have a lifetime or current history of alcohol or substance abuse/dependence 8. have had an mri two weeks prior to completing the meg scan 9. have metal braces or pacemaker that may interfere with the meg scan 10. are unable to complete the meg scan procedure follow-up assessment inclusion criteria: subjects who completed protocol adg 08-01 will be contacted and invited to participate in the follow-up assessment.

Keywords: alzheimer's disease diagnosis neuronal function cognitive impairment magnetoencephalography
study on the serum metabolic markers and early complications after allo-hsct： cohort study

Conditions: Stem Cell Transplant Complications; Acute Graft Versus Host Disease; Acute Kidney Injury; Major Adverse Cardiac Events

Summary: this study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. all patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.the primary objective is to explore the serum metabolic markers of acute graft versus host disease，acute kidney injury, and major adverse cardiac events within 100 days after transplantation，the secondary objective is to observe the high-risk factors for early complications.

this study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. all patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. baseline characterisitcs of patients, including gender, age, disease type, transplant type, donor gender and age, pre-transplant baseline electrocardiogram, myocardial enzymology, renal function, and other indicators were recorded. serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.the primary objective is to explore the serum metabolic markers of acute graft versus host disease，acute kidney injury, and major adverse cardiac events within 100 days after transplantation，the secondary objective is to observe the high-risk factors for early complications.

Eligibility criteria:
inclusion criteria: * age ≤ 65 years old; gender unlimited; normal heart and kidney function before transplantation; patients with indications for allogeneic hematopoietic stem cell transplantation. exclusion criteria: * crea or bun higher than the normal upper limit value before transplantation; individuals with a history of arrhythmia, heart failure, or pci stent implantation prior to transplantation; patients with mental illness; those who are unwilling to sign informed consent.
pain measurement and pain management in the intensive care unit(icu)

Conditions: Critically Ill Patients

Summary: the purpose of this study is to evaluate the effect of a pain training program and systematic measurement of pain scores on actual pain levels and the use of analgesics in critically ill patients.

systematic evaluation of pain, though still not common practice in all icus, is recommended in clinical practice guidelines for optimal pain management. pain is a frequently experienced problem in patients in the intensive care unit(icu). in search of literature to support the need for introduction of a pain management system and to train the entire health staff in our department little information was found concerning the effects of pain training and pain management systems in the icu. the small number of available studies may be explained by the difficulty of systematic pain measurement in icu patients, mainly due to the inability to communicate effectively with these patients.

Eligibility criteria:
inclusion criteria: * all patients admitted to the icu of the st. antonius hospital, \>18 years old. exclusion criteria: * patients who are suspected to be brain-dead

Keywords: pain scores critically ill patients icu pain management pain measurement
systematic screening for risk-factors for ulcer bleeding before anti-thrombotic treatment

Conditions: Coronary Occlusion/Thrombosis; Peptic Ulcer Hemorrhage

Summary: in a prospective randomised study design to investigate, if a systematic risk factor screening for bleeding ulcer in patients, who following percutaneous coronary intervention (pci) commence a one year combination treatment with low dose aspirin and clopidogrel, followed by prophylactic treatment with a proton pump inhibitor (ppi) in case of increased risk, can reduce the risk of bleeding ulcer. based on the recently raised suspicion that ppi's, possibly except pantoprazole, reduce the effect of adp-receptor inhibitors, pantoprazole has been chosen as prophylaxis in the screening group, and analyses will be done to ascertain whether ppi treatment increases the risk of coronary events. further analyses will be made to see whether ppi prophylaxis in high risk patients can increase compliance with the antithrombotic treatment through a reduction of side effects, thereby reducing the risk of myocardial infarction in particular stent thrombosis. the study population will be analyzed further to identify the patients, who will benefit the most from ppi prophylaxis hypothesis: screening heart patients for risk factors for bleeding ulcer and subsequently treating high risk patients with ppi can reduce the incidence of bleeding ulcer and increase compliance with the antithrombotic treatment; thereby possibly reducing the risk of coronary events and improving survival. initial a description of the prevalence of risk factors will be done.


Eligibility criteria:
inclusion criteria: * patients who has had a pci with stenting or balloon dilatation in the cardiology department at odense university hospital, århus university hospital and ålborg sygehus, where subsequent treatment with low-dose aspiring and clopidogrel or another thienopyridine is planned for one year. exclusion criteria: * previous pci with stenting or balloon dilatation * treatment with clopidogrel prior to pci * lack of informed consent
prospective evaluation of the connected emy biofeedback probe in the management of stress urinary incontinence.

Conditions: Stress Urinary Incontinence

Summary: after birth, the perineum has to be trained in order to recover its functions. this study is designed to assess the quality of life evolution with the emy connected device. the secondary purposes are to evaluate patient compliance to the emy probe, to observe the evolution of urine scores over the duration of the trial in order to consider a comparative study thereafter, and to evaluate the interest of using the emy connected perineal probe in the context of stress urinary incontinence.


Eligibility criteria:
inclusion criteria: * women with urinary leakage, at least once a week or more since more than 3 months * women aged 18 and over, no upper age limit * patient having given birth since 6 months minimum * patient able to do an effective voluntary contraction and avoiding abdominal synergy and apnea during contraction (attested by the health professional partner who leads the patient to the study) * patient who has responded favorably to a perineal reeducation with at least 2 sessions (attested by the health professional partner who leads the patient to the clinical study), rehabilitation of stress urinary incontinence or mixed incontinence with predominance of stress urinary incontinence * signed informed consent form * effective contraception throughout the study (declarative) * the patient must have a smartphone running at least the android 5 and ios 8 versions * the patient must know how to read and write french exclusion criteria: * patient practicing any other perineal reeducation during the study period * patient with neurological disease or congenital malformation, urinary incontinence or prolapse treated surgically or medically or perineal hypoesthesia or local conditions that prohibit the use of an intravaginal device * patient with an urge urinary incontinence or mixed urinary incontinence with a predominance of urgency. * contraindication to the use of the medical device * patient with genito-urinary cancer (in the last 5 years) * patient with extra-uretral "incontinence" (fistula, ectopic ureter) * patient with severe urinary retention * patient carrying a sacral neuromodulation case * subject in exclusion period (determined by previous or current study) * impossibility to give the patient clear information (patient in emergency situation, patient with difficulties for understanding, ...) * patient under the protection of justice * patient under guardianship or curatorship * pregnancy (positive urine test) * breastfeeding patient
the value of sintilimab consolidation therapy after definitive concurrent chemoradiotherapy for locally advanced thoracic esophageal cancer

Conditions: Esophageal Squamous Cell Carcinoma

Summary: esophageal cancer is a kind of disease with high incidence and mortality. definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma. to investigate the value of immunotherapy consolidation in locally advanced esophageal squamous cell carcinoma after completing radical concurrent chemoradiotherapy.

in east countries, especially china, more than 75 percent of esophageal cancers are primary squamous cell cancers located in the middle and upper thoracic segments, whereas adenocarcinoma accounted for less than 20 percent.unlike other malignancies, more than half of esophageal cancer were diagnosed as locally advanced at the time of diagnosis. definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma. immune checkpoint inhibitors are a new class of antitumor drugs. they are different from traditional cytotoxic chemotherapy drugs and can target the regulatory molecules that play an inhibitory role in the tumor immune system. recent clinical studies had shown that for locally advanced non-small cell lung cancer, maintenance therapy with the immune checkpoint inhibitor could significantly improve the overall survival for locally advanced non-small cell lung cancer after definitive concurrent chemoradiotherapy. moreover, the immune checkpoint inhibitor pd-1 has also been shown to be a promising anticancer agent in esophageal cancers. therefore, the present study intended to give a standard dose (50.4gy/28f) to locally advanced esophageal squamous cell carcinoma for radical chemoradiotherapy, and than to give the sintilimab as consolidation therapy for 1 year after completion of radiotherapy. at the time point of 6 weeks after radiotherapy, all participates need a full evaluation of the treatment response. in patients with residual disease, we would give them an additional radiotherapy boost to 61.2 gy/34f under the guidance of pet-ct or ultrasound endoscopy.

Eligibility criteria:
inclusion criteria: * ecog 0-1; life expectancy \>6 months; * stage ii/iii esophageal cancer; * pathology confirmed squamous cell carcinoma; * hemoglobin ≥10g/dl, wbc ≥3.0 x 109/l, platelet ≥100 x 109/l; cr≤ 1.0x normal upper limit, total bilirubin ≤ 1.5x normal upper limit, ast and alt≤ 1.5x normal upper limit, akp≤ 2.5x normal upper limit; * have a full understanding of this study, participate voluntarily, have follow-up conditions and sign the informed consent; exclusion criteria: * stage iv esophageal cancer; * esophageal adenocarcinoma; * gastric esophageal junction adenocarcinoma; * ecog \> 2; * progression after first-course radiotherapy; * existing active infection, such as active tuberculosis, hepatitis, etc.;

Keywords: chemoradiotherapy esophageal squamous cell carcinoma immunotherapy
effect of support for low-income mothers of preterm infants

Conditions: Preterm Birth; Low; Birthweight, Extremely (999 Grams or Less)

Summary: preterm birth is a leading cause of childhood mortality and developmental disabilities. socioeconomic disparities in the incidence of preterm birth and morbidities, mortality, and quality of care for preterm infants persist. an important predictor of the long-term consequences of preterm birth is maternal presence during the prolonged infant hospitalization (weeks to months) in the neonatal intensive care unit (nicu). mothers who visit the nicu can pump breast milk, directly breastfeed and engage in skin-to-skin care, which facilitates breast milk production and promotes infant physiologic stability and neurodevelopment. low-income mothers face significant barriers to frequent nicu visits, including financial burdens and the psychological impact of financial stress, which hinder their participation in caregiving activities. the investigators will conduct an randomized controlled trial (rct) to test the effectiveness of financial transfers among 420 medicaid - eligible mothers with infants 24 - 34 weeks' gestation in four level 3 nicus: boston medical center (bmc) in boston, massachusetts, umass memorial medical center (umass) in worcester, massachusetts, baystate medical center in springfield, massachusetts, and grady memorial hospital in atlanta, georgia. mothers in the intervention arm will receive usual care enhanced with weekly financial transfers and will be informed that these transfers are meant to help them spend more time with their infant in the nicu vs. a control arm (usual care). the primary hypothesis is that financial transfers can enable economically disadvantaged mothers to visit the nicu, reduce the negative psychological impacts of financial distress, and increase maternal caregiving behaviors associated with positive preterm infant health and development.


Eligibility criteria:
inclusion criteria: * mother is eligible for medicaid insurance. * has an infant or infants born 24 0/7-34 1/7 weeks gestation. * mother's baby is cared for at one of the four enrolling study sites located in massachusetts or georgia. * mother is eligible to breastfeed (per hospital criteria). exclusion criteria: * mother is not english- or spanish-speaking.
cardio-respiratory events during ophthalmic artery chemotherapy for retinoblastoma under a deep anesthesia

Conditions: Retinoblastoma

Summary: background: serious adverse cardio-respiratory events (scre) occur during super selective ophthalmic artery chemotherapy for retinoblastoma in children. scre mechanism remains unclear but may be attributed to an autonomic nervous reflex induced by catheterization of the ophthalmic artery. the investigators hypothesize that inadequacy between depth of anesthesia and catheter stimulation might be a support cause of these scre. methods: children requiring super selective ophthalmic artery chemotherapy for retinoblastoma are prospectively included in this observational study. endovascular procedures are performed under standardized and deep general anesthesia with sevoflurane, sufentanil and rocuronium. scre are strictly pre-defined and included arterial hypotension, bradycardia and bronchospasm. scre are recorded and the factors influencing their occurrence are investigated.


Eligibility criteria:
inclusion criteria: * superselective ophthalmic artery chemotherapy for retinoblastoma required exclusion criteria: * no
prospective, single-arm, multicenter study to evaluate the effectiveness and safety of endovascular treatment in patients with cerebral aneurysms using p64 and p48 flow-diverter stents

Conditions: Cerebral Aneurysm; Thromboembolic Disease

Summary: the use of flow-diverting stents for the endovascular treatment of cerebral aneurysms has proven to be effective and efficient in several clinical studies, leading to its widespread adoption. devices with a higher number of filaments have a greater flow-diverting effect and less variation when there are changes in the caliber of the underlying vessel or in curved vessels. however, ischemic complications secondary to their implantation have been reported, prompting the development of various strategies to reduce their thrombogenicity. phenox is the only company to date that has developed an anti-thrombogenic coating, known as hpc (hydrophilic polymer coating), which, when applied to the p64 mw hpc and p48 mw hpc devices, has shown to reduce the likelihood of thromboembolic complications associated with their implantation.

the goal of this study is to evaluate the effectiveness and safety of endovascular treatment for cerebral aneurysms using the flow-diverting stents p64mw (flow modulation device) hpc and p48mw hpc in the routine clinical practice of several spanish hospitals. it is therefore an observational study, carried out with devices already commercialized. the success rate of the intervention, the rate of hemorrhagic and thromboembolic complications, as well as variables related to the clinical and radiological follow-up of patients over a 12-month period, will be analyzed.

Eligibility criteria:
inclusion criteria: * patients over 18 years old with incidental, symptomatic, and/or ruptured cerebral aneurysms. * signed informed consent by the patient or their representative. exclusion criteria: * patients under 18 years of age. * absence of signed informed consent by the patient or their representative. * known, medically untreatable allergy to iodinated contrast. * pregnant women or those breastfeeding.

Keywords: cerebral aneurysm flow-diverting stents thrombogenicity p64 mw hpc p48 mw hpc
phase 1 dose escalation study of cgx1321 in subjects with advanced gastrointestinal tumors

Conditions: Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Bile Duct Carcinoma; Hepatocellular Carcinoma; Esophageal Carcinoma; Gastrointestinal Cancer

Summary: this is a multi-center, open label, repeat dose, phase 1 study consisting of a dose escalation phase and a dose expansion phase to evaluate safety, pharmacokinetics, and clinical activity.

the purpose of the dose escalation phase is to examine the safety and determine the maximum tolerated dose of cgx1321 when administered to subjects with advanced gi tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment. once the dose is identified in the dose escalation phase, the dose expansion phase will start. the purpose of the dose expansion phase is to continue to examine the safety and confirm the final phase 2 dose of cgx1321 when administered to subjects with advanced gi tumors who meet the entry criteria.

Eligibility criteria:
inclusion criteria: * histologically-diagnosed advanced gl tumors, such as colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, bile duct carcinoma, hepatocellular carcinoma, esophageal carcinoma that have relapsed or are refractory to or are not considered medically suitable to receive standard of care treatment * eastern cooperative oncology group (ecog) score of 0 - 1 * minimum estimated life expectancy of 3 months * adequate organ function * recovery from prior treatment-related toxicities * ability to swallow capsules * willingness for subjects of reproductive potential to use adequate methods of contraception during and for 3 months after study treatment exclusion criteria: * prior exposure to a wnt inhibitor * received previous therapy for malignancy within 21 days * major surgery within 4 weeks of first dose of study drug * radiotherapy within 2 weeks of first dose of study drug * significant gi or variceal bleeding or subdural hematoma within 3 months of treatment start * uncontrolled central nervous system metastases or leptomeningeal metastases * requirement for immunosuppressive agents (must be off for at least 7 days) * currently receiving medications that are known cyp3a4/5 inhibitors. patients currently receiving medications of known inducers of cyp3a4/5 or substrates of cyp2c8/9 and cyp1a2 may be excluded. * bone abnormalities * hypercalcemia * cardiac abnormalities * known human immunodeficiency virus positive, or active hepatitis a, b or c * history of additional prior malignancy with the exception of surgically cured carcinomas such as skin, prostate, bladder, thyroid, cervix or other carcinomas in situ * active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start * pregnancy or lactation